ATAI
mental health disorders are one of the global health burdens most recently exacerbated by covid global market size in mental health was in and is expected to grow to by objective is to achieve clinically meaningful and sustained behavioral change in mental health patients by developing rapid acting and patient centric pharmaceutical and digital treatment solutions has clinical stage drug development programs with a focus on compound classes with prior evidence in humans portfolio approach to avoid binary risk and to optimize likelihood of success validation of operating model and ability to capture value of compass pathways in and licensing deal between and subsidiary perception in strong cash position of as of and access to up to an additional from term loan facility with lead to anticipated cash runway into life sciences everywhere can more ear it life so that everyone | ATAI
Company
Deck Type
Sector
Industry
Deck date
February 2023
Slide
3 of 33
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
January 2024
mental health disorders are one of the global health burdens in in every people or million people around the world were living with a mental disorder objective is to achieve clinically meaningful and sustained behavioral change in mental health patients by developing rapid acting and durable therapeutics eight clinical stage drug development programs and strategic investments each with a robust package of prior clinical evidence validated operating model and ability to capture value of compass pathways in and licensing deal between and subsidiary perception in cash marketable securities and committed term loan funding are expected to provide runway into life sciences healing so that everyone everywhere can live more life | ATAI
Investor Presentation
October 2023
mental health disorders are one of the global health burdens in in every people or million people around the world were living with a mental disorder objective is to achieve clinically meaningful and sustained behavioral change in mental health patients by developing rapid acting and durable therapeutics six clinical stage drug development programs each with a robust package of prior clinical evidence validated operating model and ability to capture value of compass pathways in and licensing deal between and subsidiary perception in strong cash position with anticipated cash runway into including access to facility life sciences healing so that everyone everywhere can live more life | ATAI
Investor Conference
May 2023
life sciences healing mental health disorders so that everyone everywhere can live a more life | ATAI
Investor Presentation
April 2023
mental health disorders are one of the global health burdens most recently exacerbated by covid global market size in mental health was in and is expected to grow to by objective is to achieve clinically meaningful and sustained behavioral change in mental health patients by developing rapid acting and patient centric pharmaceutical and digital treatment solutions has multiple clinical stage drug development programs with focus on compound classes that all have prior evidence in humans portfolio approach to avoid binary risk and to optimize likelihood of success validation of operating model and ability to capture value of compass pathways in and licensing deal between and subsidiary perception in strong cash position of as of and access to up to an additional from term loan facility with lead to anticipated cash runway into life sciences healing everywhere can live a more life so everyone | ATAI
Related slides by other companies
Bausch Health Companies
Results
November 2022
reconciliation of reported cash provided by operating activities to cash flows from operations non health | Bausch Health Companies
Jefferies Financial Group
Investor Day
October 2022
global cash equities market share growth | Jefferies Financial Group
Gatos Silver
Results
November 2023
highlights strong cash flows and increased production guidance strong balance sheet cash balance of at debt free robust operating and financial results at continued strong cash flow generation clear pathway to further mine life extension and growth increased full year and production guidance mine life extended to end capital efficient margin improvement and expansion options | Gatos Silver
Bausch Health Companies
Results
May 2023
reconciliation of reported cash provided by operating activities to adjusted cash flows from operations excluding non | Bausch Health Companies
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io